Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008; 133(Suppl 6):381S-453S. 8th ed
[2]
American Academy of Orthopaedic Surgeons. Clinical guideline on pulmonary embolism in patients undergoing total hip or knee arthroplasty [citado en mayo de 2007]. Disponible en: http://wwwaaosorg/Research/guidelines/PE_guidelinepdf.
[3]
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25:5490-505.
[4]
Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007; 64:69-76.
[5]
Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost. 2007; 5:1610-6.
[6]
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370:949-56.
[7]
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5:2178-85.
[8]
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24:1-9.
[9]
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358:2765-75.
[10]
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372:31-9.
[11]
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358:2776-86.
[12]
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009; 373:1673-80.
[13]
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361:594-604.
[14]
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
[15]
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-52.
[16]
Human albumin administration in critically ill patients: systematic review of randomised controlled, trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998; 317:235-40.
[17]
Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med. 1999; 27:200-10.
[18]
Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001; 135:149-64.
[19]
Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med. 2004; 32:2029-38.
[20]
A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995; 155:373-9.
[21]
Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med. 2004; 170:1247-59.
[22]
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008; 36:296-327.
[23]
Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ. 1998; 316:961-4.
[24]
7.5% sodium chloride/dextran for resuscitation of trauma patients undergoing helicopter transport. Arch Surg. 1991; 126:1065-72.
[25]
Prehospital resuscitation of hypotensive trauma patients with 7.5% NaCl versus 7.5% NaCl with added dextran: a controlled trial [discussion 32–3]. J Trauma. 1993; 34:622-32.
[26]
Hypertonic solutions in the treatment of hypovolemic shock: a prospective, randomized study in patients admitted to the emergency room. Surgery. 1992; 111:380-5.
[27]
Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolemic patients. Shock. 1997; 7:79-83.
[28]
Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial. Ann Surg. 1991; 213:482-91.
[29]
Efficacy of hypertonic 7.5% saline and 6% dextran-70 in treating trauma: a meta-analysis of controlled clinical studies. Surgery. 1997; 122:609-16.
[30]
Efficacy of hypertonic saline dextran (HSD) in patients with traumatic hypotension: meta-analysis of individual patient data. Acta Anaesthesiol Scand Suppl. 1997; 110:77-9.
[31]
Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. J Trauma. 1997; 42(Suppl 5):S61-5.
[32]
The use of hypertonic saline in the treatment of traumatic brain injury. J Trauma. 2001; 50:367-83.
[33]
Prehospital hypertonic saline resuscitation of patients with hypotension and severe traumatic brain injury: a randomized controlled trial. JAMA. 2004; 291:1350-7.
[34]
Hypertonic resuscitation of hypovolemic shock after blunt trauma: a randomized controlled trial [discussion 49]. Arch Surg. 2008; 143:139-48.
[35]
Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006; 60(Suppl 6):S3-S11.
[36]
Strategies for transfusion therapy. Best Pract Res Clin Anaesthesiol. 2004; 18:661-73.
[37]
Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006; 60(Suppl 6):S91-6.
[38]
Factor VIIa (recombinant) for acute traumatic hemorrhage. Am J Health Syst Pharm. 2008; 65:1616-23.
[39]
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials [discussion 8]. J Trauma. 2005; 59:8-15. discussion-8
[40]
The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003; 55:886-91.
[41]
Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit Care. 2006; 10:R104.
[42]
How accurate is weight estimation in the emergency department?. Emerg Med Australas. 2005; 17:113-6.
[43]
Dosing and monitoring NovoSeven treatment. Haemostasis. 1996; 26(Suppl 1):102-8.
[44]
Management of bleeding following major trauma: a European guideline. Crit Care. 2007; 11:R17.
[45]
Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005; 3:640-8.
[46]
Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharmacy & Therapeutics. 2005; 30:644-58.
